PKS Advisory Services LLC Takes Position in iCAD, Inc. (NASDAQ:ICAD)

PKS Advisory Services LLC purchased a new position in shares of iCAD, Inc. (NASDAQ:ICAD) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 29,089 shares of the technology company’s stock, valued at approximately $53,000. PKS Advisory Services LLC owned approximately 0.11% of iCAD as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the business. waypoint wealth counsel raised its stake in iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after acquiring an additional 4,400 shares in the last quarter. Thompson Davis & CO. Inc. bought a new position in iCAD in the 4th quarter valued at approximately $31,000. Summit Trail Advisors LLC acquired a new stake in iCAD in the fourth quarter valued at approximately $214,000. Finally, First Eagle Investment Management LLC grew its stake in shares of iCAD by 6.1% during the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock worth $1,311,000 after buying an additional 41,000 shares during the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.

iCAD Trading Down 3.1 %

iCAD stock opened at $2.20 on Thursday. The stock has a 50-day moving average price of $2.67 and a two-hundred day moving average price of $2.08. iCAD, Inc. has a 12 month low of $1.18 and a 12 month high of $3.78. The company has a market capitalization of $58.39 million, a PE ratio of -16.92 and a beta of 1.95.

iCAD (NASDAQ:ICAD) last issued its quarterly earnings data on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%. The business had revenue of $5.41 million during the quarter, compared to analyst estimates of $4.72 million.

Analyst Ratings Changes

Separately, StockNews.com upgraded iCAD from a “sell” rating to a “hold” rating in a research note on Wednesday.

iCAD Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.